Business Context and Reporting Period
This Form 8-K Current Report was filed by Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) on January 24, 2025, covering events occurring on January 21, 2025. The filing addresses a change in the Company's Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to corporate governance updates and does not contain financial performance data.
Material Changes
On January 21, 2025, James S. Scibetta resigned from the Board of Directors effective immediately. Consequently, he also resigned from his positions on the Audit and Compensation Committees. The Company stated that the resignation was due to Mr. Scibetta's other professional obligations and was not the result of any material disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, or new risk factors. No unusual items or contingencies were disclosed in this report.
Key Facts for Investors to Verify
- James S. Scibetta's resignation from the Board and its committees was effective immediately as of January 21, 2025.
- The resignation was attributed to other professional obligations, not a disagreement with the Company.
- The Company has not yet announced a replacement director in this filing.
- No financial data or operational updates were included in this specific report.